Nuwellis Q2 2021 Earnings Report
Key Takeaways
Nuwellis, Inc. reported a record quarterly revenue of $2.5 million for the second quarter of 2021, a 35% increase compared to the prior year period. The company ended the quarter with $24.0 million in cash and no debt.
Reported record quarterly revenue of $2.5 million, a 35 percent increase compared to the prior year period
Realized strong sequential growth across all customer markets and recorded the sixth consecutive quarter with double-digit revenue growth vs. prior year
Received Category III CPT code for the use of therapeutic ultrafiltration, effective January 1, 2022
Ended the quarter with $24.0 million in cash and no debt
Nuwellis
Nuwellis
Forward Guidance
The Company expects quarterly revenue to continue increasing sequentially for the remainder of 2021 as it continues to build its commercial presence and seeks to increase utilization of Aquadex therapy. This outlook includes several assumptions, including no significant change in utilization or procedure volumes associated with COVID-19 resurgences.